In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 376 to 400 of 447

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Soticlestat for treating seizures associated with Dravet syndrome in people 2 years and over TSID 12091	Technology appraisal guidance	TBC
Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over TSID 10632	Technology appraisal guidance	TBC
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287]	Technology appraisal guidance	TBC
SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals)	Medical technologies guidance	TBC
Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668]	Technology appraisal guidance	21 April 2021
Spesolimab for preventing generalised pustular psoriasis flares [ID6216]	Technology appraisal guidance	TBC
Spesolimab for preventing generalised pustular psoriasis flares in people 12 years and over [TSID12086]	Technology appraisal guidance	TBC
Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]	Technology appraisal guidance	TBC
Surgical insertion of a catheter-based intravascular microaxial flow pump for cardiogenic shock	Interventional procedures guidance	25 March 2026
Surgical mesh for ventral hernias	Health technology evaluation	TBC
Surgical vessel sealing systems (MT798)	Medical technologies guidance	TBC
Suspected cancer update	Quality standard	TBC
Suspected Cancer: recognition and referral (update)	NICE guideline	25 March 2026
Suspected sepsis in pregnancy: recognition, diagnosis and early management	NICE guideline	17 February 2027
Suspected sepsis in under 16s: recognition, diagnosis and early management	NICE guideline	17 February 2027
Suspected sepsis: recognition, diagnosis and early management	NICE guideline	TBC
Suspected sepsis: recognition, diagnosis and early management - procalcitonin testing	NICE guideline	15 July 2026
Tafasitamab with lenalidomide and R-CHOP for untreated high-intermediate-risk or high-risk diffuse large B-cell lymphoma [ID6568]	Technology appraisal guidance	10 June 2027
Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments ID6413	Technology appraisal guidance	15 July 2026
Talacotuzumab for untreated acute myeloid leukaemia [ID1262]	Technology appraisal guidance	TBC
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]	Technology appraisal guidance	3 December 2025
Targeted-release budesonide for treating primary IgA nephropathy (review of TA937) [ID6485]	Technology appraisal guidance	11 February 2026
Tarlatamamb for treating extensive stage small-cell lung cancer that has progressed after platinum-based chemotherapy [ID6617]	Technology appraisal guidance	TBC
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401	Technology appraisal guidance	TBC
Technologies to support self-monitoring of vision change for people with macular disease (provisional title)	Health technology evaluation	TBC

Results per page

10
25
50
All